Statement of Principles concerning cerebral meningioma (Balance of Probabilities) (No. 2 of 2018)

The central legal-technical concepts the SoP deploys are: the defined injury or disease; a closed list of qualifying factors; temporal and quantitative thresholds; and the requirement that any qualifying factor be related to the person's relevant service. The condition covered is defined narrowly: a "primary benign or intermediate grade tumour of the cerebral meninges" (s 7(2)). Although ICD‑10‑AM codes D32.0 and D32.9 are noted as attracting to the condition, the operative meaning is the definition in subsection 7(2) rather than the code alone (s 7(3)-(4)).

"Factors that must exist" constitute the SoP's operative gate. At least one of the enumerated factors in section 9 must exist for a finding that cerebral meningioma or death from cerebral meningioma is connected with relevant service on the balance of probabilities (s 9). The factors are expressed in measurable terms where possible: ionising radiation cumulative equivalent dose of at least 0.5 sievert to the brain with a minimum ten-year latency (s 9(1)); obesity defined by Body Mass Index (BMI) of 30 or greater for at least ten years within the 20 years before clinical onset (s 9(2) and Schedule 1); pregnancy in specified peripartum windows at onset or worsening (s 9(3), s 9(5)); treatment with cyproterone acetate at daily dose ≥15 mg for continuous at least one year within ten years before onset or worsening (s 9(4), s 9(6)); and “inability to obtain appropriate clinical management” (s 9(7)). The instrument treats clinical onset and clinical worsening as distinct events for timing purposes. Those terms are used but not separately defined in the instrument, leaving their application to clinical assessment and decision-makers.

"Relationship to service" is an explicit legal constraint. The existence of any qualifying factor must be related to the person's relevant service (s 10(1)). The SoP also specifies that factors in subsections 9(5) to 9(7) only apply to material contribution to, or aggravation of, the condition where the person's cerebral meningioma was suffered or contracted before or during, but did not arise out of, their relevant service (s 10(2)). Thus the SoP differentiates between primary causation and aggravation/material contribution in relation to service timing.

Two cross-referential concepts anchor measurement and external standards. First, "cumulative equivalent dose" is defined by reference to an external ARPANSA guide and excludes normal background radiation (Schedule 1). That ties dose reconstruction to a specified methodology and creates a procedural requirement for assessing radiation exposure. Second, body mass is calculated by the BMI formula W/H2 as defined in Schedule 1, which operationalises the obesity threshold. Finally, "death from cerebral meningioma" expressly includes cases where the tumour contributed to a terminal event, with "terminal event" defined by reference to proximate or ultimate causes such as pneumonia or respiratory failure (s 7(5) and Schedule 1).

The SoP affects veterans and members of the Forces who lodge claims under parts of the VEA or MRCA that require a finding of connection between injury or disease and relevant service. Section 5 limits application to a claim to which section 120B of the VEA or section 339 of the MRCA applies. Those provisions are cited as the operational contexts in which the SoP will be applied by decision-makers, meaning claimants seeking entitlements under those parts of the VEA or MRCA are the primary affected group (s 5).

Operationally, the instrument affects several procedural actors. Decision-makers under the VEA and MRCA will use the SoP as the medical framework for assessing causation or material contribution. The Repatriation Medical Authority is the issuing body and supplies the SoP for use by those decision-makers (s 3, s 8). Medical practitioners who provide evidence for claims will be affected by the SoP’s specific thresholds and definitions; they must supply records and opinions that demonstrate whether the required factors, including timings and dose thresholds, are met. For example, clinicians will need to document dates of clinical onset and clinical worsening, pregnancy timing relative to onset or worsening, medication dosing and continuity, and BMI history over decades (s 9; Schedule 1).

Administrative and technical experts will also be affected. Radiation dose reconstruction is governed by the Guide to calculation of 'cumulative equivalent dose' prepared by the Australian Radiation Protection and Nuclear Safety Agency and specified by the instrument as the methodology for calculating dose (Schedule 1). Persons responsible for compiling employment, service, medical, and radiation exposure records will face the task of assembling documentary and possibly expert evidence to quantify exposures and timings.

The instrument also affects the legal advisers and advocates who prepare claims. The discrete, measurable factors and their temporal requirements set a narrow evidentiary path claimants must follow. For instance, the radiation threshold requires a cumulative equivalent dose of at least 0.5 sievert to the brain at least ten years prior to clinical onset (s 9(1)); obesity requires a BMI of 30 or greater for at least ten years within the 20 years preceding onset (s 9(2)). Those numerical thresholds determine what documentary and expert proof will be necessary for successful claims.

Finally, the SoP affects circumstances where the disease precedes service. Section 10(2) limits certain factors to material contribution or aggravation only where the disease was suffered or contracted before or during, but not arising out of, relevant service. That means claimants whose tumours pre-dated service face a different evidentiary pathway to show worsening or material contribution, rather than primary causation.

The SoP does not create new statutory duties or criminal sanctions. Its operative legal function is to set out the medical-scientific criteria that must be applied to assess whether cerebral meningioma or death from cerebral meningioma is connected with relevant service on the balance of probabilities. The principal "duties" are administrative and evidentiary rather than punitive. Decision-makers are to apply the SoP when deciding claims to which section 120B of the VEA or section 339 of the MRCA applies (s 5). The Authority declares it is of the view, on the sound medical‑scientific evidence available, that it is more probable than not that the condition can be related to relevant service (s 8); decision-makers will use that framework in exercising their discretion under the VEA and MRCA.

For claimants, the relevant "rights" are procedural: to have their claim assessed against the SoP. If the specified factors in section 9 are satisfied and are shown to be related to relevant service as required by section 10(1), a decision-maker may find connection on the balance of probabilities. The instrument therefore informs claimants and their advisers about what must be proved medically to establish a service connection.

On the duty side, practitioners and experts preparing evidence for claims will need to align their medico-legal reports with the SoP’s definitions and thresholds. For example, reporting must show the BMI calculation and duration if obesity is relied on (Schedule 1). Where radiation exposure is claimed, dose reconstruction must follow the ARPANSA guide specified in the Schedule 1 definition of cumulative equivalent dose. That requirement creates a duty on whoever performs the dose estimate to use the Guide methodology and to exclude normal background radiation exposure (Schedule 1).

Decision-makers have a duty to take the SoP into account. Section 11 provides that if a factor in this SoP refers to an injury or disease covered by a different Statement of Principles determined under subsection 196B(3) of the VEA, the factors in that other SoP apply in accordance with its terms as in force from time to time (s 11). That cross-referencing places an administrative duty on decision-makers to locate and apply the relevant SoPs when factors overlap with other conditions.

There is a practical duty on claimants and their advisors to establish both the medical factor and that the factor is related to the person’s relevant service. Section 10(1) makes the relation to service a necessary element. For factors tied to timing or dosages, the instrument creates the duty to produce documentary or expert evidence proving dates and quantities. Failure to do so is consequential because the SoP requires at least one of the enumerated factors to be established before a service connection can be found (s 9).

The SoP does not, however, prescribe procedures for appeals, review, or the ultimate granting of benefits. Those procedural rights and duties remain governed by the VEA and MRCA provisions that frame claims and reviews, which are the contexts in which the SoP operates (s 5).

This instrument contains no criminal offences, civil penalties, or enforcement provisions. It is a non‑penal medical-scientific determination intended to guide administrative decision-making under the VEA and the MRCA. There are no penalty clauses within the SoP text and no delegated enforcement powers conferred by the document itself. Its legal effect lies in influencing coverage decisions under existing statutory frameworks rather than imposing sanctions on actors.

Enforcement, in functional terms, occurs through administrative decision-making and adjudication of claims. The SoP provides the evidentiary criteria decision-makers will use to determine whether cerebral meningioma or death from cerebral meningioma is connected with relevant service on the balance of probabilities (s 8, s 9). That means that if a claimant cannot show at least one of the enumerated factors and its relation to relevant service, decision-makers may determine that the condition is not connected with service and therefore deny the claim or deny the relevant element of the claim. Denial of entitlements or benefits is an administrative outcome, not a penalty imposed by the SoP.

The instrument does not prescribe how decision-makers are to record their assessment or to treat borderline cases, nor does it set timetables or compliance reporting requirements. It does, however, reference external, authoritative measurement methodology for radiation dose calculation (Schedule 1). Non-use of the specified ARPANSA guide for cumulative equivalent dose estimation would likely be material to a review of the administrative decision, since the SoP expressly requires that methodology for dose calculation (Schedule 1). That creates an enforcement risk in appellate or review proceedings where the absence of methodological conformity could be raised.

Where factors in this SoP overlap with factors governed by other Statements of Principles, section 11 requires decision-makers to apply the other Statements in accordance with their terms. That is a procedural enforcement point: decision-makers must ensure the applicable Statements are located and applied together when relevant.

Finally, the SoP’s revocation of the earlier 2009 instrument (s 4) has enforcement implications for which version of the SoP applies to particular claims made after the commencement date. The SoP commences on 29 January 2018 (s 2); decision-makers will apply the 2018 instrument to claims to which the specified claim sections of the VEA or MRCA apply from that date forward. The instrument does not itself state transitional arrangements; any contention over which SoP applies to claims will be resolved within the statutory decision-review framework of the VEA and MRCA rather than by penalties in the SoP.

This SoP is an instrument produced under subsection 196B(3) of the Veterans' Entitlements Act 1986 and explicitly applies to claims within the statutory frameworks of the VEA and the MRCA, namely to claims to which section 120B of the VEA or section 339 of the MRCA applies (s 3, s 5). It does not amend either statute; rather, it is a medical-scientific input for decision-makers when applying those statutes. Section 11 expressly provides for cross-referencing to other Statements of Principles determined under subsection 196B(3) of the VEA: if a factor in this SoP refers to an injury or disease covered by another SoP, the factors in that other SoP apply as in force from time to time (s 11). That requires decision-makers to reconcile and apply multiple SoPs when conditions overlap.

The instrument invokes external technical standards that have legal significance within its operation. The Schedule defines "cumulative equivalent dose" by reference to the Guide to calculation of 'cumulative equivalent dose' published by the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), "as in force on 2 August 2017" (Schedule 1). That ties the SoP to an external methodology for dose reconstruction and integrates that methodology into the statutory decision-making chain. Similarly, the SoP refers to ICD‑10‑AM codes (D32.0 and D32.9) as attracting to cerebral meningioma but clarifies that the operative meaning is the definition in subsection 7(2) (s 7(2)-(4)). Those references mean the SoP interacts with international and national classification systems and with specialist agency guidance for technical measurements.

Where the SoP’s factors refer to injuries or diseases covered by other SoPs, section 11 requires application of those other Statements "in accordance with the terms of that Statement of Principles as in force from time to time" (s 11). That introduces an operation whereby a decision-maker must identify all relevant SoPs and apply each on its own terms, which may require reconciling definitions, thresholds, or temporal requirements.

The SoP revokes the prior Statement of Principles concerning cerebral meningioma No. 20 of 2009, as amended (s 4). That revocation is an interaction point with prior instruments and may affect decisions depending on timing and any transitional rules under the VEA or MRCA claims processes. The instrument itself contains no transitional provisions; its commencement date is specified (s 2), and decision-makers and advisers must determine which SoP applies to a given claim in light of that timing.

Finally, the SoP operates within but does not alter the standard of proof or procedural rules in the VEA or MRCA. Section 8 records the Authority's view "on the sound medical‑scientific evidence available" that it is more probable than not that the condition can be related to relevant service; this ties the SoP to the balance of probabilities standard. How that standard is implemented in statutory decision-making, review, and appeal procedures remains governed by the VEA and MRCA themselves rather than by the SoP.

The instrument identifies itself as "Statement of Principles concerning cerebral meningioma (Balance of Probabilities) (No. 2 of 2018)" and is dated 22 December 2017 with a commencement date of 29 January 2018 (title, s 1, s 2). It was made under subsection 196B(3) of the Veterans' Entitlements Act 1986 (s 3). Section 4 explicitly revokes the earlier Statement of Principles concerning cerebral meningioma No. 20 of 2009, as amended, which had been made under subsections 196B(3) and (8) of the VEA (s 4).

Beyond the express revocation of the 2009 instrument, the text contains no schedules or provisions that indicate subsequent amendments or a history of variations; the instrument as presented is a standalone instrument reflecting the RMA’s updated medical-scientific view as at its date. The Schedule 1 definitions are integral to the current instrument and thereby replace any inconsistent definitional material in the revoked 2009 instrument.

The instrument’s use of external documents is time-stamped. The guide for calculation of cumulative equivalent dose is referenced "as in force on 2 August 2017" (Schedule 1). That temporal qualification has two implications. First, the SoP requires dose reconstructions to follow the version of the ARPANSA guide specified as at that date. Second, because the Schedule ties the definition to a dated edition of the Guide, any later amendments to the ARPANSA guide post‑dating 2 August 2017 would not automatically be incorporated unless the SoP is itself amended or the definition is interpreted as allowing the more recent guide "as in force" , but the Schedule uses the date to fix the version in use. The instrument does not otherwise address the process or effect of future amendments to the ARPANSA guide or to ICD‑10‑AM.

The instrument does not include transitional provisions explaining how claims in progress, or decisions made under the revoked 2009 SoP, are to be handled. The commencement and revocation provisions (s 2, s 4) give the dates for operation of the 2018 instrument and the end of operation of the 2009 instrument, but they do not detail retroactivity or processing of existing claims. Those matters remain to be resolved within the governing statutes and administrative practice.

No further amendment entries, repeals, or savings clauses appear in the instrument as supplied. Any subsequent amendments to this SoP would be reflected in later instruments made under the VEA powers and would need to be checked against the Repatriation Medical Authority’s public determinations and the consolidated legislative instrument record.

The instrument contains no references to judicial or tribunal decisions, and the text does not record any litigation concerning its terms. It is a medical-scientific determination rather than a judicial ruling and thus forms part of the administrative evidence base used by decision-makers applying the VEA and MRCA. The SoP itself does not compile or cite cases and contains no note of litigation in its text.

Because the SoP is an administrative medical determination, disputes about its application or about findings of fact in individual claims would arise in the statutory review and appeal processes provided in the VEA and MRCA. Any litigation or tribunal decisions challenging findings of connection between cerebral meningioma and service would be handled through those statutory paths. The instrument does not reference decisions or authorities that have considered its provisions, nor does it record prior judicial interpretation of the earlier 2009 SoP.

Users of this SoP should therefore expect that any litigation history relevant to the interpretation or application of the SoP will be found in decisions under the VEA and MRCA rather than within the SoP itself. This instrument does not preclude judicial review of administrative decisions that apply it; however, the SoP’s own text contains no litigation record, and no case law is supplied within the instrument to indicate how courts or tribunals have interpreted these particular factors or thresholds.

When advising clients or compiling claims, practitioners should therefore plan for the possibility that questions of interpretation , for example, the meaning of "clinical onset" or "inability to obtain appropriate clinical management", or the admissibility and sufficiency of dose reconstruction evidence prepared under the ARPANSA guide , may be matters for review, appeal, or judicial attention in individual cases. The instrument itself does not record outcomes or precedents on those interpretive points.

Several discrete features of the SoP are potential pitfalls for claimants, advisers, clinicians, and decision-makers because they impose strict, measurable thresholds or leave key terms open to clinical interpretation.

1. Requirement that at least one enumerated factor exist. The SoP’s gate is categorical. Section 9 states that at least one of the listed factors must exist before it can be said on the balance of probabilities that cerebral meningioma or death from cerebral meningioma is connected with relevant service (s 9). If evidence does not meet any one of these enumerated factors, the SoP does not provide an alternative pathway to establish service connection. Claimants reliant on other plausible causal hypotheses not listed in s 9 will find no support in this SoP.

2. Timing and latency constraints. Several factors include precise timing thresholds. For ionising radiation, the cumulative equivalent dose must be at least 0.5 sievert to the brain at least ten years before clinical onset (s 9(1)). For obesity, a BMI ≥30 must have persisted for at least ten years within the 20 years before clinical onset (s 9(2)). For cyproterone acetate, the daily dose must be at least 15 mg for at least one continuous year within ten years before clinical onset or worsening (s 9(4), s 9(6)). These numeric thresholds create evidentiary hurdles and temporal windows that claimants must document precisely.

3. Definition and measurement of cumulative equivalent dose. The Schedule defines cumulative equivalent dose by reference to the ARPANSA Guide "as in force on 2 August 2017" and excludes normal background radiation (Schedule 1). Dose reconstruction therefore must follow that methodology. The Guide requires combining dose estimates across exposure types and calculating dose averaged over tissue mass. Those technical requirements impose the need for specialist radiation experts and source documentation. Failure to apply the specified Guide could be fatal to a radiation exposure claim.

4. Clinical terms left undefined. The SoP hinges on clinical events labelled "clinical onset" and "clinical worsening", but the instrument does not define those terms. This creates a potential interpretive battleground over when onset or worsening occurred for timing purposes. Decision-makers and medical experts will need to reconcile the date of symptom onset, imaging detection, biopsy, or other markers to satisfy temporal requirements. Absent a definition in the SoP, claimants may face disputes over which clinical milestone counts.

5. Pregnancy windows are narrow. The pregnancy-related factors require being in the second or third trimester of pregnancy, or within 30 days postpartum, at the time of clinical onset or clinical worsening (s 9(3), s 9(5)). Early pregnancy and later postpartum periods outside 30 days are not captured by these factors. Documenting exact pregnancy stage relative to clinical events will therefore be important.

6. Medication dosing and continuity requirements. The cyproterone acetate factors require a specific minimum daily dose (15 mg) and a continuous period of at least one year within ten years before onset or worsening (s 9(4), s 9(6)). Intermittent treatment, lower doses, or gaps in the treatment record risk failing the continuity and dose tests. Prescribing records, pill counts, pharmacy dispensing records, and treating physician statements will be needed.

7. "Inability to obtain appropriate clinical management" is vague. Section 9(7) allows inability to obtain appropriate clinical management to be a qualifying factor. The instrument does not define "appropriate clinical management", nor does it specify how evidence of inability is to be demonstrated. This open-ended factor could be subject to wide interpretation and will likely require detailed evidence of service-related lack of access, refusals, delays, or systemic barriers, plus medical opinion linking lack of management to clinical outcomes.

8. Relationship-to-service requirement. Section 10(1) requires that the existence of any s 9 factor must be related to the person's relevant service. That is an element separate from proving the factor itself. Consequently, claimants must show both that the factor existed and that it is connected to service. For example, radiation exposure must be attributable to activities that fall within relevant service as defined by the Schedule, and obesity must be shown to have occurred during a period related to the service where that relationship is material.

9. Aggravation/material contribution limits. Factors in subsections 9(5) to 9(7) apply only to material contribution to, or aggravation of, cerebral meningioma where the tumour was suffered or contracted before or during, but did not arise out of, the person's relevant service (s 10(2)). That means these factors cannot be used to establish primary causation of a tumour that first arose after service unless they meet the general factors in s 9 and are related to service per s 10(1). Claimants with pre-existing tumours must therefore satisfy the narrower pathway for aggravation.

10. ICD‑10‑AM codes attract but do not determine meaning. The instrument notes that cerebral meningioma attracts ICD‑10‑AM code D32.0 or D32.9 but that the meaning for the SoP is the definition in subsection 7(2) (s 7(3)). Reliance on coding alone without evidence of histology and clinical grade that aligns with the definition may be insufficient.

11. Revocation of prior SoP. The 2018 instrument revokes the 2009 SoP (s 4). Claimants and advisers must determine which instrument applies to a given claim depending on timing and the statutory application provisions. The instrument contains no transitional directions; that issue is resolved in the statutory decision process, but misapplying the SoP version could affect outcomes.

12. No penalties but administrative consequence. The SoP does not create sanctions; however, failure to meet its criteria will result in administrative denial of service connection under the VEA or MRCA, which has significant practical consequences for entitlements and medical treatment coverage.

Each of these points is grounded in the instrument’s text and should be considered when assessing prospects and preparing evidentiary material for claims that rely on this SoP.

Compliance in this context means preparing and presenting evidence that enables a decision-maker to find, on the balance of probabilities, that at least one of the section 9 factors existed and that the factor was related to the person's relevant service as required by section 10(1). The SoP’s discrete, measurable criteria allow for a checklist-style approach to assembling proof.

1. Establish the clinical diagnosis and grade. Obtain medical records confirming the diagnosis of cerebral meningioma as defined in subsection 7(2), including pathology, imaging, and clinical notes that demonstrate the tumour is a primary benign or intermediate grade tumour of the cerebral meninges. Where ICD‑10‑AM coding is used, ensure the clinical documentation substantiates the meaning in subsection 7(2) rather than relying on code alone (s 7(2)-(4)).

2. Document clinical onset and clinical worsening. Compile contemporaneous clinical notes, imaging dates, surgical or biopsy dates, symptom onset records, and treating specialists’ statements to identify the dates of clinical onset and any clinical worsening. Because the SoP uses those dates to calculate latency windows and eligibility for pregnancy and medication-related factors, clear documentation is essential (s 9; s 10(2)).

3. For radiation exposure claims, calculate cumulative equivalent dose per the ARPANSA Guide. Locate all records of potential exposures, including service records (positions, duties, deployments), records of presence during or subsequent to nuclear tests, medical diagnostic or therapeutic radiation procedures, and occupational exposures (Schedule 1 Note 1). Commission dose reconstruction following the Guide specified in Schedule 1 as in force on 2 August 2017. Ensure the calculation excludes normal background radiation and combines multiple sources appropriately, averaged over the specific tissue mass (Schedule 1). Engage a radiation expert familiar with the ARPANSA methodology to produce a report showing that the cumulative equivalent dose to the brain was at least 0.5 sievert and that the exposure occurred at least ten years before clinical onset (s 9(1); Schedule 1).

4. For obesity claims, assemble BMI history. Use medical records, employment medicals, service health records, and other contemporaneous weight and height measurements to compute BMI values (Schedule 1). Demonstrate that BMI was 30 or greater for at least ten years within the 20 years before clinical onset (s 9(2)). Because BMI requires W/H2, ensure consistent units and that measurements are documented for the relevant timeframe.

5. For pregnancy-related factors, gather obstetric records. Obtain antenatal and peripartum records to show that the claimant was in the second or third trimester, or within 30 days postpartum, at the time of clinical onset or clinical worsening (s 9(3), s 9(5)). Precise dating of gestational age and delivery date will be required to meet the narrow windows set out.

6. For cyproterone acetate treatment, secure prescribing and dispensing records. Obtain specialist notes, prescriptions, pharmacy dispensing histories, and treating physician statements to show daily dosing of at least 15 mg for at least one continuous year within the ten years before clinical onset or clinical worsening (s 9(4), s 9(6)). If continuous use is disputed, collect corroborating notes on adherence.

7. For inability to obtain appropriate clinical management, compile administrative and clinical evidence. Because the SoP does not define "appropriate clinical management", supply records showing attempts to access care, referrals, denials, delays, geographic or service-related barriers, and treating clinicians’ opinions that lack of appropriate management materially contributed to clinical outcomes (s 9(7)). Link those access problems to the timing of clinical onset or worsening, and to the person's relevant service if that is the basis of the inability to obtain management (s 10(1), s 10(2)).

8. Prove relation to relevant service. For each factor relied on, produce service records, deployment logs, occupational histories, or other documentation establishing that the factor is related to the claimant’s relevant service as defined in the Schedule (eligible war service, defence service, or peacetime service) (Schedule 1 definitions; s 10(1)). For radiation, that will include establishing that the exposure occurred during or as a result of service-related activities. For obesity or medication-related claims, explain how the factor relates temporally and causally to the service circumstances if that relation is asserted.

9. Cross-check with other Statements of Principles. If any factor refers to another injury or disease covered by a different SoP, identify and apply the other SoP’s factors per section 11. Assemble evidence that satisfies both this SoP and any overlapping SoPs in accordance with their respective terms (s 11).

10. Use expert medical opinions tied to the SoP. Medical specialists should be asked to address the precise legal thresholds in the SoP (for example, the ten-year latency period for radiation, the one-year minimum continuous drug exposure, BMI duration and window). Experts should state whether, on the balance of probabilities, the relevant factor existed and was related to the person’s relevant service, and whether the factor materially contributed to or aggravated the condition where that is the asserted pathway.

11. Document death linkage where applicable. If the claim concerns death from cerebral meningioma, assemble death certificates, clinical records around the terminal event, and medical opinion linking the tumour to the proximate or ultimate cause of death in the Schedule’s list of terminal events (s 7(5); Schedule 1).

12. Prepare for application of the 2018 SoP. The instrument commenced on 29 January 2018 and revoked the 2009 SoP (s 2, s 4). Confirm which SoP governs the claim depending on the timing and the relevant statutory provisions under the VEA and MRCA, and prepare evidence to the standards of the 2018 instrument if it applies.

13. Anticipate evidentiary challenges. Expect that decision-makers will scrutinise continuity of treatment records, precise dosage and timing, and the methodological fidelity of dose reconstruction. Where possible, gather contemporaneous records rather than relying on recollection, and obtain experts who can explain the ARPANSA methodology and the clinical milestones in terms the decision-maker can apply against the SoP’s thresholds.

Following these steps aligns evidence gathering and expert opinions with the SoP’s defined thresholds and temporal requirements, and therefore with the evidentiary pathway that decision-makers will use when applying the VEA and MRCA provisions referenced by the instrument.